Investments
27Portfolio Exits
8Funds
2Partners & Customers
1About Avlar BioVentures
Avlar is a biotechnology venture capital company which currently has over Euro150 million under management in Avlar BioVentures Fund I, Avlar BioVentures Fund II and the First Cambridge Gateway Fund. The funds are focused on seed and early-stage investments and are used to invest in biopharmaceutical, small molecule drug discovery, epigenetics, medtech and related biotechnology opportunities, and some technology ventures.
Want to inform investors similar to Avlar BioVentures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Avlar BioVentures Investments
27 Investments
Avlar BioVentures has made 27 investments. Their latest investment was in Medical Device Innovations as part of their Seed VC on November 11, 2011.
Avlar BioVentures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/28/2011 | Seed VC | Medical Device Innovations | $0.7M | Yes | ||
10/12/2009 | Seed VC | Crescendo Biologics | $7.1M | Yes | 1 | |
10/22/2007 | Series A | CellCentric | $4.3M | No | ||
7/6/2006 | Series D | |||||
10/25/2005 | Seed VC |
Date | 11/28/2011 | 10/12/2009 | 10/22/2007 | 7/6/2006 | 10/25/2005 |
|---|---|---|---|---|---|
Round | Seed VC | Seed VC | Series A | Series D | Seed VC |
Company | Medical Device Innovations | Crescendo Biologics | CellCentric | ||
Amount | $0.7M | $7.1M | $4.3M | ||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 1 |
Avlar BioVentures Portfolio Exits
8 Portfolio Exits
Avlar BioVentures has 8 portfolio exits. Their latest portfolio exit was Paradigm Therapeutics on April 02, 2007.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
4/2/2007 | Acquired | ||||
Date | 4/2/2007 | ||||
|---|---|---|---|---|---|
Exit | Acquired | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources |
Avlar BioVentures Fund History
2 Fund Histories
Avlar BioVentures has 2 funds, including Avlar BioVentures Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
7/27/2001 | Avlar BioVentures Fund II | Early-Stage Venture Capital | Closed | $60.82M | 1 |
2/1/2000 | Avlar BioVentures Fund I |
Closing Date | 7/27/2001 | 2/1/2000 |
|---|---|---|
Fund | Avlar BioVentures Fund II | Avlar BioVentures Fund I |
Fund Type | Early-Stage Venture Capital | |
Status | Closed | |
Amount | $60.82M | |
Sources | 1 |
Avlar BioVentures Partners & Customers
1 Partners and customers
Avlar BioVentures has 1 strategic partners and customers. Avlar BioVentures recently partnered with Excalibur on .
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
Partner | Slovakia (Slovak Republic) | based life science venture capital groups and Ergomed , an international provider of drug development services announced today that they have entered an agreement to carry out a Phase II study with Oral BVT .115959 - a novel A2A agonist in diabetic neuropathic pain . | 1 |
Date | |
|---|---|
Type | Partner |
Business Partner | |
Country | Slovakia (Slovak Republic) |
News Snippet | based life science venture capital groups and Ergomed , an international provider of drug development services announced today that they have entered an agreement to carry out a Phase II study with Oral BVT .115959 - a novel A2A agonist in diabetic neuropathic pain . |
Sources | 1 |
Avlar BioVentures Team
3 Team Members
Avlar BioVentures has 3 team members, including former Chief Executive Officer, David A Gough.
Name | Work History | Title | Status |
|---|---|---|---|
David A Gough | Chief Executive Officer | Former | |
Name | David A Gough | ||
|---|---|---|---|
Work History | |||
Title | Chief Executive Officer | ||
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
